Vanguard Group
ATXS

Vanguard Group’s Astria Therapeutics ATXS Stock Holding History

Vanguard Group’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$34.3M Sell
2,623,042
-19,128
-0.7% -$228K ﹤0.01% 2366
2025
Q3 		$19.2M Buy
2,642,170
+117,510
+5% +$795K ﹤0.01% 2647
2025
Q2 		$13.5M Sell
2,524,660
-123,592
-5% -$599K ﹤0.01% 2746
2025
Q1 		$14.1M Sell
2,648,252
-29,101
-1% -$204K ﹤0.01% 2663
2024
Q4 		$23.9M Buy
2,677,353
+41,833
+2% +$444K ﹤0.01% 2509
2024
Q3 		$29M Buy
2,635,520
+45,360
+2% +$504K ﹤0.01% 2412
2024
Q2 		$23.6M Buy
2,590,160
+54,269
+2% +$530K ﹤0.01% 2486
2024
Q1 		$35.7M Buy
2,535,891
+480,184
+23% +$5.98M ﹤0.01% 2314
2023
Q4 		$15.8M Buy
2,055,707
+545,786
+36% +$3.02M ﹤0.01% 2700
2023
Q3 		$11.3M Buy
1,509,921
+2,905
+0.2% +$24.8K ﹤0.01% 2824
2023
Q2 		$12.6M Buy
1,507,016
+190,163
+14% +$2.19M ﹤0.01% 2816
2023
Q1 		$17.5M Buy
1,316,853
+662,527
+101% +$8.96M ﹤0.01% 2645
2022
Q4 		$9.74M Buy
654,326
+123,173
+23% +$1.27M ﹤0.01% 2957
2022
Q3 		$4.8M Buy
531,153
+27,743
+6% +$186K ﹤0.01% 3348
2022
Q2 		$1.51M Sell
503,410
-29,158
-5% -$131K ﹤0.01% 3934
2022
Q1 		$3.57M Hold
532,568
– – ﹤0.01% 3684
2021
Q4 		$2.87M Sell
532,568
-21,330
-4% -$140K ﹤0.01% 3893
2021
Q3 		$4.9M Buy
553,898
+418,782
+310% +$4.01M ﹤0.01% 3674
2021
Q2 		$1.71M Sell
135,116
-10,469
-7% -$136K ﹤0.01% 4007
2021
Q1 		$2.52M Buy
145,585
+8,332
+6% +$151K ﹤0.01% 3810
2020
Q4 		$1.76M Buy
137,253
+1,881
+1% +$33.5K ﹤0.01% 3696
2020
Q3 		$5.03M Buy
135,372
+11,241
+9% +$445K ﹤0.01% 3139
2020
Q2 		$4.79M Buy
124,131
+11,474
+10% +$409K ﹤0.01% 3115
2020
Q1 		$2.81M Buy
112,657
+42,355
+60% +$1.31M ﹤0.01% 3202
2019
Q4 		$2.49M Hold
70,302
– – ﹤0.01% 3386
2019
Q3 		$2.28M Buy
70,302
+1,177
+2% +$46.5K ﹤0.01% 3412
2019
Q2 		$3.35M Buy
69,125
+9,526
+16% +$432K ﹤0.01% 3308
2019
Q1 		$2.83M Buy
59,599
+18,407
+45% +$624K ﹤0.01% 3347
2018
Q4 		$1.08M Sell
41,192
-388
-0.9% -$14.7K ﹤0.01% 3549
2018
Q3 		$2M Sell
41,580
-409
-1% -$18.4K ﹤0.01% 3528
2018
Q2 		$2.42M Buy
41,989
+32,244
+331% +$2.97M ﹤0.01% 3440
2018
Q1 		$1.06M Buy
9,745
+465
+5% +$46.5K ﹤0.01% 3636
2017
Q4 		$829K Buy
9,280
+3,612
+64% +$425K ﹤0.01% 3652
2017
Q3 		$721K Buy
5,668
+1,715
+43% +$143K ﹤0.01% 3674
2017
Q2 		$337K Sell
3,953
-2,195
-36% -$183K ﹤0.01% 3798
2017
Q1 		$590K Buy
6,148
+2,409
+64% +$332K ﹤0.01% 3721
2016
Q4 		$810K Sell
3,739
-1
-0% -$245 ﹤0.01% 3625
2016
Q3 		$1.38M Buy
3,740
+1,472
+65% +$388K ﹤0.01% 3495
2016
Q2 		$504K Sell
2,268
-160
-7% -$48.2K ﹤0.01% 3794
2016
Q1 		$734K Buy
2,428
+253
+12% +$87.2K ﹤0.01% 3683
2015
Q4 		$1.03M Buy
2,175
+294
+16% +$141K ﹤0.01% 3620
2015
Q3 		$913K Buy
1,881
+414
+28% +$296K ﹤0.01% 3657
2015
Q2 		$1.07M Buy
+1,467
New +$1.11M ﹤0.01% 3641

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group's ATXS Position: Q4 2025 in Review

Vanguard Group reduced its Astria Therapeutics (ATXS) stake by 0.72% in Q4 2025, selling an estimated $228K and leaving 2,623,042 shares worth $34.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2366.

Vanguard Group first reported a position in ATXS in Q2 2015 and has held it in 43 quarters since. The position peaked at $35.7M in Q1 2024. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

  • Vanguard Group held 2,623,042 shares of Astria Therapeutics worth $34.3M as of Q4 2025.
  • Vanguard Group sold 19,128 Astria Therapeutics shares in Q4 2025, an estimated $228K.
  • Astria Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2366 holding.
  • Vanguard Group first reported a position in Astria Therapeutics in Q2 2015 and has held it in 43 quarters since.
  • Vanguard Group's Astria Therapeutics position peaked at $35.7M in Q1 2024.
  • 141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.